Droxidopa

CAT: 804-HY-13458-01Size: 5 mgDry Ice: NoHazardous: No
5 mgSelected
AVAILABILITY
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Droxidopa (L-DOPS; SM5688) is a potent, orally active norepinephrine precursor. Droxidopa increases standing blood pressure, ameliorates symptoms of orthostatic hypotension and improves standing ability. Droxidopa has the potential for the research of neurogenic orthostatic hypotension (nOH) and alternative ADHD (attention deficit hyperactivity disorder) [1][2][3][4].
CAS Number
[23651-95-8]
Product Name Alternative
L-DOPS; DOPS; SM5688
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
Adrenergic Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/droxidopa.html
Purity
98.80
Solubility
DMSO : 21.74 mg/mL (ultrasonic; warming; adjust pH to 3 with 1 M HCl; heat to 60°C)
Smiles
OC1=C(O)C=CC([C@@H](O)[C@@H](C(O)=O)N)=C1
Molecular Formula
C9H11NO5
Molecular Weight
213.19
Precautions
H315, H319, H335
References & Citations
[1]Horacio Kaufmann, et al. Droxidopa for neurogenic orthostatic hypotension. Neurology, 2014; 83 (4) .|[2]Dela Peña I, et al. Droxidopa alters dopamine neuron and prefrontal cortex activity and improves attention-deficit/hyperactivity disorder-like behaviors in rats. Eur J Pharmacol. 2021 Feb 5;892:173826.|[3]Cao LF, et al. Restoring Spinal Noradrenergic Inhibitory Tone Attenuates Pain Hypersensitivity in a Rat Model of Parkinson's Disease. Neural Plast. 2016;2016:6383240. |[4]Kaufmann H. L-dihydroxyphenylserine (Droxidopa) : a new therapy for neurogenic orthostatic hypotension: the US experience. Clin Auton Res. 2008 Mar;18 Suppl 1:19-24.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched

Related Products

CatalogName